RenovoRx CEO Shaun Bagai will present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference on June 23, 2026, highlighting the company's record first quarter 2026 revenue driven by strong demand for its FDA-cleared RenovoCath drug-delivery device. He will provide updates on the Phase III TIGeR-PaC clinical trial for pancreatic cancer, expected to complete enrollment by end of June 2026 with final data in mid-to-late 2027. The company also recently received FDA Orphan Drug Designation for oxaliplatin in pancreatic cancer, potentially granting seven years of market exclusivity. RenovoRx is expanding adoption of RenovoCath at major cancer centers and advancing its targeted oncology therapies pipeline.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Frasers Group PLC has withheld financial guidance for the upcoming year due to uncertainty around its takeover bids for Hugo Boss and Accent Group. The retailer's full-year adjusted profit before tax fell 4% to £538 million, impacted by asset impairm...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
